glp·helper
glphelper.com/semaglutide/florida/cape-coral
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Cape Coral, FL

Verified Semaglutide providers in Cape Coral, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
24
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
25 of 25 shown

Find a Semaglutide provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /semaglutide/florida/{city}
§ 03Getting Semaglutide in Cape Coral
25 providers · Cape Coral, FL

How to get Semaglutide in Cape Coral.

25 GLP-1 prescribers and 7 local resource types are on record for Cape Coral, plus 3 nearby towns in the directory.

Prescribers in Cape Coral
25 prescribers
25 GLP-1 prescribers in Cape Coral, most listed as Family Medicine (12), Internal Medicine (9) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Fort Myers (31 providers), Port Charlotte (30 providers) and North Port (28 providers).
Around the prescription in Cape Coral
7 listed nearby
28 dietitians, 10 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Cape Coral.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Cape Coral

Cape Coral, Florida has a population of 194,016 people. The adult obesity rate in Cape Coral is an age-adjusted estimate of 30.4%, 0.8 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 10.2% of adults in Cape Coral. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.5% of adults in Cape Coral.

of Cape Coral adults have obesity
30.4%
diagnosed diabetes
10.2%
no regular physical activity
23.5%

Age-adjusted estimates for Cape Coral, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Semaglutide in Cape Coral
6 nutritionists

The prescription is one part. Here is the rest, in Cape Coral.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Cape Coral, FL, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tina Anderson, RD,LDN, MPH, CDE
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1235536293
Melanie Aracri, RD LD CDE
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1477524650
Erika Graziani, M.S., R.D., L.D
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1316132699
Alayna Horvath, RD, RDN
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1245843622
Timothy Katz, RD, CDCES
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1588431423
Jessica Quigley, RD, CDE
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1255939922

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Crunch Fitness - Cape Coral
GYM
4.5 on Google · 1867 reviews
244 Nicholas Pkwy W
Website
LA Fitness
GYM
4.2 on Google · 1032 reviews
2301 Del Prado Blvd S
Website
Planet Fitness
GYM
4.4 on Google · 982 reviews
1502 Del Prado Blvd S B
Website
Anytime Fitness
GYM
4.7 on Google · 668 reviews
2708 Santa Barbara Blvd
Website
CrossFit ENG
GYM
5.0 on Google · 589 reviews
326 SW 2nd Terrace
Website
Hammerhead Gym (Cape Coral)
GYM
4.9 on Google · 251 reviews
1013 Cape Coral Pkwy E
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Florida

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]